Neurocrine Biosciences
NBIX
274 hedge funds and large institutions have $9.03B invested in Neurocrine Biosciences in 2018 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 98 increasing their positions, 96 reducing their positions, and 30 closing their positions.
30% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 30
18% more capital invested
Capital invested by funds: $7.63B → $9.03B (+$1.39B)
3% more funds holding
Funds holding: 266 → 274 (+8)
5% more call options, than puts
Call options by funds: $73.1M | Put options by funds: $69.3M
2% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 96
0.94% less ownership
Funds ownership: 103.16% → 102.23% (-0.94%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$73.5M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$34.7M |
| 3 |
Two Sigma Investments
New York
|
+$29.2M |
| 4 |
Two Sigma Advisers
New York
|
+$24.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$47.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$33.2M |
| 3 |
Goldman Sachs
New York
|
-$30.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.9M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$28.5M |
NBIX Hedge Fund Activity: Q2 2018 in Review
274 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2018, worth a combined $9.03B — up 18% from $7.63B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new NBIX positions and 30 closed out — a net gain of 9 holders — while 98 added to existing stakes and 96 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $73.5M. The largest seller was Franklin Resources, cutting an estimated $47.5M.
- 274 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2018, up from 266 in Q1 2018.
- Funds reported $9.03B of Neurocrine Biosciences stock for Q2 2018, up 18% quarter-over-quarter.
- 39 funds opened new Neurocrine Biosciences positions in Q2 2018 and 30 closed out, a net change of +9 holders.
- The largest Neurocrine Biosciences buyer in Q2 2018 was Point72 Asset Management, an estimated $73.5M added.
- The largest Neurocrine Biosciences seller in Q2 2018 was Franklin Resources, an estimated $47.5M sold.
Based on aggregated 13F filings for Q2 2018.